An Update into Rentosertib in IPF: Scaling AI-Discovered Therapies into Late-Stage Development
- Revisiting TNIK inhibition as a therapeutic strategy in IPF and reflecting on how AI-enabled discovery has progressed from candidate identification to multi-program clinical advancement
- Updates on Phase 2b progression in the US, Phase 3 initiation in China, and the strategic considerations behind multinational late-stage expansion
- Advancing an inhaled IPF programme into Phase 1 and discussing how formulation strategy, delivery route, and lifecycle planning may shape future positioning in an increasingly competitive IPF landscape